AssetMark Inc
IMVT icon

AssetMark Inc’s Immunovant IMVT Stock Holding History

AssetMark Inc’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51K Hold
117
– – ﹤0.01% 2725
2026
Q1 		$2.91K Hold
117
– – ﹤0.01% 2744
2025
Q4 		$2.97K Buy
117
+5
+4% +$111 ﹤0.01% 2649
2025
Q3 		$1.8K Sell
112
-21
-16% -$340 ﹤0.01% 2648
2025
Q2 		$2.13K Sell
133
-2,188
-94% -$33.1K ﹤0.01% 2411
2025
Q1 		$39.7K Sell
2,321
-289
-11% -$6.05K ﹤0.01% 1503
2024
Q4 		$64.7K Sell
2,610
-281
-10% -$7.97K ﹤0.01% 1347
2024
Q3 		$82.4K Buy
2,891
+1,228
+74% +$36.2K ﹤0.01% 1182
2024
Q2 		$43.9K Buy
1,663
+24
+1% +$683 ﹤0.01% 1260
2024
Q1 		$53K Buy
1,639
+182
+12% +$6.64K ﹤0.01% 1152
2023
Q4 		$61.4K Buy
+1,457
New +$53.6K ﹤0.01% 1119

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AssetMark Inc's IMVT Position: Q2 2026 in Review

AssetMark Inc held its Immunovant (IMVT) position steady in Q2 2026 at 117 shares worth $4.51K. The position accounts for ﹤0.01% of the portfolio, ranked #2725.

AssetMark Inc first reported a position in IMVT in Q4 2023 and has held it in 11 quarters since. The position peaked at $82.4K in Q3 2024. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • AssetMark Inc held 117 shares of Immunovant worth $4.51K as of Q2 2026.
  • AssetMark Inc left its Immunovant share count unchanged in Q2 2026.
  • Immunovant made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2725 holding.
  • AssetMark Inc first reported a position in Immunovant in Q4 2023 and has held it in 11 quarters since.
  • AssetMark Inc's Immunovant position peaked at $82.4K in Q3 2024.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.